Aberrant host defense against Leishmania major in the absence of SLPI

Journal of Leukocyte Biology

Volumn 96, Issue 5, 2014, Pages 917-929

  McCartney Francis, Nancy ^a   Jin, Wenwen ^a   Belkaid, Yasmine ^b   McGrady, George ^a   Wahl, Sharon M ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

IFN ; Macrophage polarization; NO; Parasite; SOCS

Indexed keywords

ARGINASE; GAMMA INTERFERON; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 4; LEUKOCYTE ELASTASE; MONOCYTE CHEMOTACTIC PROTEIN 1; RNA; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SUPPRESSOR OF CYTOKINE SIGNALING 1; AUTACOID; SOCS1 PROTEIN, MOUSE; SUPPRESSOR OF CYTOKINE SIGNALING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HOST RESISTANCE; IN VIVO STUDY; INFECTION CONTROL; INNATE IMMUNITY; LEISHMANIA MAJOR; MACROPHAGE CULTURE; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; PARASITE CLEARANCE; PARASITE LOAD; POLARIZATION; PROMASTIGOTE; PROTEIN EXPRESSION; SKIN LEISHMANIASIS; WILD TYPE; ANIMAL; DEFICIENCY; DISEASE MODEL; DISEASE RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; MACROPHAGE; MACROPHAGE ACTIVATION; METABOLISM; PATHOLOGY; PHAGOCYTE;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE RESISTANCE; GENE EXPRESSION REGULATION; INFLAMMATION MEDIATORS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE II; PHAGOCYTES; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84908281017     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.4A0612-295RR     Document Type: Article

References (69)

1. Murray, H. W., Berman, J. D., Davies, C. R., Saravia, N. G. (2005) Advances in leishmaniasis. Lancet 366, 1561–1577.
2. Belkaid, Y., Kamhawi, S., Modi, G., Valenzuela, J., Noben-Trauth, N., Rowton, E., Ribeiro, J., Sacks, D. L. (1998) Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J. Exp. Med. 188, 1941–1953.
3. Sacks, D., and Sher, A. (2002) Evasion of innate immunity by parasitic protozoa. Nat. Immunol. 3, 1041–1047.
4. Malamud, D., Wahl, S. M. (2010) The mouth: a gateway or a trap for HIV? AIDS 24, 5–16.
5. Sallenave, J. M. (2010) Secretory leukocyte protease inhibitor and elafin/trappin-2: versatile mucosal antimicrobials and regulators of immunity. Am. J. Resp. Cell Mol. Biol. 42, 635–643.
6. Stetler, G., Brewer, M. T., Thompson, R. C. (1986) Isolation and sequence of a human gene encoding a potent inhibitor of leukocyte proteases. Nucleic Acids Res. 14, 7883–7896.
7. Thompson, R. C., and Ohlsson, K. (1986) Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc. Natl. Acad. Sci. U. S. A. 83, 6692–6696.
8. Franzke, C. W., Baici, A., Bartels, J., Christophers, E., Wiedow, O. (1996) Antileukoprotease inhibits stratum corneum chymotryptic enzyme: evidence for a regulative function in desquamation. J. Biol. Chem. 271, 21886–21890.
9. Zhang, Y., DeWitt, D. L., McNeely, T. B., Wahl, S. M., Wahl, L. M. (1997) Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J. Clin. Invest. 99, 894–900.
10. Song, X., Zeng, L., Jin, W., Thompson, J., Mizel, D. E., Lei, K., Billinghurst, R. C., Poole, A. R., Wahl, S. M. (1999) Secretory leukocyte pro-tease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis. J. Exp. Med. 190, 535–542.
11. McNeely, T. B., Dealy, M., Dripps, D. J., Orenstein, J. M., Eisenberg, S. P., Wahl, S. M. (1995) Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J. Clin. Invest. 96, 456–464.
12. McNeely, T. B., Shugars, D. C., Rosendahl, M., Tucker, C., Eisenberg, S. P., Wahl, S. M. (1997) Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs before viral reverse transcription. Blood 90, 1141–1149.
13. Tomee, J. F., Hiemstra, P. S., Heinzel-Wieland, R., Kauffman, H. F. (1997) Antileukoprotease: an endogenous protein in the innate mucosal defense against fungi. J. Infect. Dis. 176, 740–747.
14. Chattopadhyay, A., Gray, L. R., Patton, L. L., Caplan, D. J., Slade, G. D., Tien, H. C., Shugars, D. C. (2004) Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons. Infect. Immun. 72, 1956–1963.
15. Hiemstra, P. S., Maassen, R. J., Stolk, J., Heinzel-Wieland, R., Steffens, G. J., Dijkman, J. H. (1996) Antibacterial activity of antileukoprotease. Infect. Immun. 64, 4520–4524.
16. Ashcroft, G. S., Lei, K., Jin, W., Longenecker, G., Kulkarni, A. B., Greenwell- Wild, T., Hale-Donze, H., McGrady, G., Song, X. Y., Wahl, S. M. (2000) Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat. Med. 6, 1147–1153.
17. Zhu, J., Nathan, C., Jin, W., Sim, D., Ashcroft, G. S., Wahl, S. M., Lacomis, L., Erdjument-Bromage, H., Tempst, P., Wright, C. D., Ding, A. (2002) Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 111, 867–878.
18. Angelov, N., Moutsopoulos, N., Jeong, M. J., Nares, S., Ashcroft, G., Wahl, S. M. (2004) Aberrant mucosal wound repair in the absence of secretory leukocyte protease inhibitor. Thromb. Haemost. 92, 288–297.
19. Jin, F. Y., Nathan, C., Radzioch, D., Ding, A. (1997) Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 88, 417–426.
20. Taggart, C. C., Greene, C. M., McElvaney, N. G., O’Neill, S. (2002) Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. J. Biol. Chem. 277, 33648–33653.
21. Taggart, C. C., Cryan, S. A., Weldon, S., Gibbons, A., Greene, C. M., Kelly, E., Low, T. B., O’Neill S J., McElvaney, N. G. (2005) Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J. Exp. Med. 202, 1659–1668.
22. Ashcroft, G. S., Jeong, M. J., Ashworth, J. J., Hardman, M., Jin, W., Moutsopoulos, N., Wild, T., McCartney-Francis, N., Sim, D., McGrady, G., Song, X. Y., Wahl, S. M. (2012) Tumor necrosis factor-alpha (TNFalpha) is a therapeutic target for impaired cutaneous wound healing. Wound Repair Regen. 20, 38–49.
23. Laskay, T., van Zandbergen, G., Solbach, W. (2008) Neutrophil granulocytes as host cells and transport vehicles for intracellular pathogens: apoptosis as infection-promoting factor. Immunobiology 213, 183–191.
24. Peters, N. C., Egen, J. G., Secundino, N., Debrabant, A., Kimblin, N., Kamhawi, S., Lawyer, P., Fay, M. P., Germain, R. N., Sacks, D. (2008) In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. Science 321, 970–974.
25. Belkaid, Y., Hoffmann, K. F., Mendez, S., Kamhawi, S., Udey, M. C., Wynn, T. A., Sacks, D. L. (2001) The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J. Exp. Med. 194, 1497–1506.
26. Bogdan, C., Rollinghoff, M., Diefenbach, A. (2000) The role of nitric oxide in innate immunity. Immunol. Rev. 173, 17–26.
27. Gordon, S. (2003) Alternative activation of macrophages. Nat. Rev. 3, 23–35.
28. Gordon, S., and Martinez, F. O. (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32, 593–604.
29. Bronte, V., and Zanovello, P. (2005) Regulation of immune responses by L-arginine metabolism. Nat. Rev. 5, 641–654.
30. Corraliza, I. M., Soler, G., Eichmann, K., Modolell, M. (1995) Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10. and. PGE2) in murine bone-marrow-derived macrophages. Biochem. Biophys. Res. Commun. 206, 667–673.
31. Goerdt, S., and Orfanos, C. E. (1999) Other functions, other genes: alternative activation of antigen-presenting cells. Immunity 10, 137–142.
32. Iniesta, V., Gomez-Nieto, L. C., Corraliza, I. (2001) The inhibition of arginase by N (omega)-hydroxy-l-arginine controls the growth of Leishmania inside macrophages. J. Exp. Med. 193, 777–784.
33. Iniesta, V., Gomez-Nieto, L. C., Molano, I., Mohedano, A., Carcelen, J., Miron, C., Alonso, C., Corraliza, I. (2002) Arginase I induction in macrophages, triggered by Th2-type cytokines, supports the growth of intracellular Leishmania parasites. Parasite Immunol. 24, 113–118.
34. Modolell, M., Corraliza, I. M., Link, F., Soler, G., Eichmann, K. (1995) Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur. J. Immunol. 25, 1101–1104.
35. Rutschman, R., Lang, R., Hesse, M., Ihle, J. N., Wynn, T. A., Murray, P. J. (2001) Cutting edge: Stat6-dependent substrate depletion regulates nitric oxide production. J. Immunol. 166, 2173–2177.
36. Belkaid, Y., Mendez, S., Lira, R., Kadambi, N., Milon, G., Sacks, D. (2000) A natural model of Leishmania major infection reveals a prolonged “silent” phase of parasite amplification in the skin before the onset of lesion formation and immunity. J. Immunol. 165, 969–977.
37. Da Silva, R. P., Hall, B. F., Joiner, K. A., Sacks, D. L. (1989) CR1, the C3b receptor, mediates binding of infective Leishmania major metacyclic promastigotes to human macrophages. J. Immunol. 143, 617–622.
38. Belkaid, Y., Butcher, B., Sacks, D. L. (1998) Analysis of cytokine production by inflammatory mouse macrophages at the single-cell level: selective impairment of IL-12 induction in Leishmania-infected cells. Eur. J. Immunol. 28, 1389–1400.
39. Von Stebut, E., Belkaid, Y., Jakob, T., Sacks, D. L., Udey, M. C. (1998) Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity. J. Exp. Med. 188, 1547–1552.
40. McCartney-Francis, N. L., Mizel, D. E., Redman, R. S., Frazier-Jessen, M., Panek, R. B., Kulkarni, A. B., Ward, J. M., McCarthy, J. B., Wahl, S. M. (1996) Autoimmune Sjogren’s-like lesions in salivary glands of TGF-beta1- deficient mice are inhibited by adhesion-blocking peptides. J. Immunol. 157, 1306–1312.
41. Wen, J., Nikitakis, N. G., Chaisuparat, R., Greenwell-Wild, T., Gliozzi, M., Jin, W., Adli, A., Moutsopoulos, N., Wu, T., Warburton, G., Wahl, S. M. (2011) Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma. Am. J. Pathol. 178, 2866–2878.
42. Alexander, W. S., and Hilton, D. J. (2004) The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu. Rev. Immunol. 22, 503–529.
43. Elliott, J., and Johnston, J. A. (2004) SOCS: role in inflammation, allergy and homeostasis. Trends Immunol. 25, 434–440.
44. Wojno, E. D., and Hunter, C. A. (2012) New directions in the basic and translational biology of interleukin-27. Trends Immunol. 33, 91–97.
45. Anderson, C. F., Stumhofer, J. S., Hunter, C. A., Sacks, D. (2009) IL-27 regulates IL-10 and IL-17 from CD4+ cells in nonhealing Leishmania major infection. J. Immunol. 183, 4619–4627.
46. Ivens, A. C., Peacock, C. S., Worthey, E. A., Murphy, L., Aggarwal, G., Berriman, M., Sisk, E., Rajandream, M. A., Adlem, E., Aert, R., Anupama, A., Apostolou, Z., Attipoe, P., Bason, N., Bauser, C., Beck, A., Beverley, S. M., Bianchettin, G., Borzym, K., Bothe, G., Bruschi, C. V., Collins, M., Cadag, E., Ciarloni, L., Clayton, C., Coulson, R. M., Cronin, A., Cruz, A. K, Davies R. M., De Gaudenzi, J., Dobson, D. E., Duesterhoeft, A., Fazelina, G., Fosker, N., Frasch, A. C., Fraser, A., Fuchs, M., Gabel, C., Goble, A., Goffeau, A., Harris, D., Hertz-Fowler, C., Hilbert, H., Horn, D., Huang, Y., Klages, S., Knights, A., Kube, M., Larke, N., Litvin, L., Lord, A., Louie, T., Marra, M., Masuy, D., Matthews, K., Michaeli, S., Mottram, J. C., Muller-Auer, S., Munden, H., Nelson, S., Norbertczak, H., Oliver, K., O’Neil, S., Pentony, M., Pohl, T. M., Price, C., Purnelle, B., Quail, M. A., Rabbinowitsch, E., Reinhardt, R., Rieger, M., Rinta, J., Robben, J., Robertson, L., Ruiz, J. C., Rutter, S., Saunders, D., Schafer, M., Schein, J., Schwartz, D. C., Seeger, K., Seyler, A., Sharp, S., Shin, H., Sivam, D., Squares, R., Squares, S., Tosato, V., Vogt, C., Volckaert, G., Wambutt, R., Warren, T., Wedler, H., Woodward, J., Zhou, S., Zimmermann, W., Smith, D. F, Blackwell, J. M., Stuart, K. D., Barrell, B., and Myler, P. J. (2005) The genome of the kinetoplastid parasite, Leishmania. major. Science 309, 436–442.
47. Nishimura, J., Saiga, H., Sato, S., Okuyama, M., Kayama, H., Kuwata, H., Matsumoto, S., Nishida, T., Sawa, Y., Akira, S., Yoshikai, Y., Yamamoto, M., Takeda, K. (2008) Potent antimycobacterial activity of mouse secretory leukocyte protease inhibitor. J. Immunol. 180, 4032–4039.
48. Ma, G., Greenwell-Wild, T., Lei, K., Jin, W., Swisher, J., Hardegen, N., Wild, C. T., Wahl, S. M. (2004) Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J. Exp. Med. 200, 1337–1346.
49. Doumas, S., Kolokotronis, A., Stefanopoulos, P. (2005) Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect. Immun. 73, 1271–1274.
50. Weldon, S., Taggart, C. C. (2007) Innate host defense functions of secretory leucoprotease inhibitor. Exp. Lung Res. 33, 485–491.
51. Ben-Othman, R., Guizani-Tabbane, L., Dellagi, K. (2008) Leishmania initially activates but subsequently down-regulates intracellular mitogenactivated protein kinases and nuclear factor-kappaB signaling in macrophages. Mol. Immunol. 45, 3222–3229.
52. Ghosh, S., and Hayden, M. S. (2008) New regulators of NF-kappaB in inflammation. Nat. Rev. 8, 837–848.
53. Iniesta, V., Carcelen, J., Molano, I., Peixoto, P. M., Redondo, E., Parra, P., Mangas, M., Monroy, I., Campo, M. L., Nieto, C. G., Corraliza, I. (2005) Arginase I induction during Leishmania major infection mediates the development of disease. Infect. Immun. 73, 6085–6090.
54. Wanasen, N., Soong, L. (2008) L-arginine metabolism and its impact on host immunity against Leishmania infection. Immunol. Res. 41, 15–25.
55. Gaur, U., Roberts, S. C., Dalvi, R. P., Corraliza, I., Ullman, B., Wilson, M. E. (2007) An effect of parasite-encoded arginase on the outcome of murine cutaneous leishmaniasis. J. Immunol. 179, 8446–8453.
56. El Kasmi, K. C., Qualls, J. E., Pesce, J. T., Smith, A. M., Thompson, R. W., Henao-Tamayo, M., Basaraba, R. J., Konig, T., Schleicher, U., Koo, M. S., Kaplan, G., Fitzgerald, K. A., Tuomanen, E. I., Orme, I. M., Kanneganti, T. D., Bogdan, C., Wynn, T. A., Murray, P. J. (2008) Tolllike receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nat. Immunol. 9, 1399–1406.
57. Van den Bossche, J., Lamers, W. H., Koehler, E. S., Geuns, J. M., Alhonen, L., Uimari, A., Pirnes-Karhu, S., Van Overmeire, E., Morias, Y., Brys, L., Vereecke, L., De Baetselier, P., Van Ginderachter, J. A. (2012) Pivotal advance: arginase-1-independent polyamine production stimulates the expression of IL-4-induced alternatively activated macrophage markers while inhibiting LPS-induced expression of inflammatory genes. J. Leukoc. Biol. 91, 685–699.
58. Li, W., Katz, B. P., Spinola, S. M. (2012) Haemophilus ducreyi-induced interleukin-10 promotes a mixed M1 and M2 activation program in human macrophages. Infect. Immun. 80, 4426–4434.
59. Sacks, D., Noben-Trauth, N. (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. 2, 845–858.
60. Belkaid, Y. (2007) Regulatory T cells and infection: a dangerous necessity. Nat. Rev. 7, 875–888.
61. Anderson, C. F., Mendez, S., Sacks, D. L. (2005) Nonhealing infection despite Th1 polarization produced by a strain of Leishmania major in C57BL/6 mice. J. Immunol. 174, 2934–2941.
62. El-Gayar, S., Thuring-Nahler, H., Pfeilschifter, J., Rollinghoff, M., Bogdan, C. (2003) Translational control of inducible nitric oxide synthase by IL-13 and arginine availability in inflammatory macrophages. J. Immunol. 171, 4561–4568.
63. Naderer, T., and McConville, M. J. (2008) The Leishmania-macrophage interaction: a metabolic perspective. Cell. Microbiol. 10, 301–308.
64. Nagase, H., Jones, K. M., Anderson, C. F., Noben-Trauth, N. (2007) Despite increased CD4+Foxp3+ cells within the infection site, BALB/c IL-4 receptor-deficient mice reveal CD4+Foxp3-negative T cells as a source of IL-10 in Leishmania major susceptibility. J. Immunol. 179, 2435–2444.
65. Sano, C., Shimizu, T., Sato, K., Kawauchi, H., Tomioka, H. (2000) Effects of secretory leucocyte protease inhibitor on the production of the anti-inflammatory cytokines, IL-10 and transforming growth factor-beta (TGF-beta), by lipopolysaccharide-stimulated macrophages. Clin. Exp. Immunol. 121, 77–85.
66. Jin, F., Nathan, C. F., Radzioch, D., Ding, A. (1998) Lipopolysacchariderelated stimuli induce expression of the secretory leukocyte protease inhibitor, a macrophage-derived lipopolysaccharide inhibitor. Infect Immun. 66, 2447–2452.
67. Alexander, W. S., Starr, R., Fenner, J. E., Scott, C. L., Handman, E., Sprigg, N. S., Corbin, J. E., Cornish, A. L., Darwiche, R., Owczarek, C. M., Kay, T. W., Nicola, N. A., Hertzog, P. J., Metcalf, D., Hilton, D. J. (1999) SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98, 597–608.
68. Briken, V., and Mosser, D. M. (2011) Editorial: switching on arginase in M2 macrophages. J. Leukoc. Biol. 90, 839–841.
69. Whyte, C. S., Bishop, E. T., Ruckerl, D., Gaspar-Pereira, S., Barker, R. N., Allen, J. E., Rees, A. J., Wilson, H. M. (2011) Suppressor of cytokine signaling (SOCS)1 is a key determinant of differential macrophage activation and function. J. Leukoc. Biol. 90, 845–854.